Cover Image

老年癡呆症:醫藥品 vs. 藥用植物 - 市場·競爭企業·機會分析與預測2015-2020年

Alzheimer's disease: Pharmacuetical drugs vs. Medicnal plants - Markets, competitors and opportunities: 2015-2020 analysis and forecasts

出版商 Amadee & Company, Inc. 商品編碼 334103
出版日期 內容資訊 英文 77 Pages
Back to Top
老年癡呆症:醫藥品 vs. 藥用植物 - 市場·競爭企業·機會分析與預測2015-2020年 Alzheimer's disease: Pharmacuetical drugs vs. Medicnal plants - Markets, competitors and opportunities: 2015-2020 analysis and forecasts
出版日期: 2015年07月06日 內容資訊: 英文 77 Pages




  • 報告的目的
  • 調查手法和資訊來源
  • 統計相關註解


  • 老年癡呆症概要
  • 膽鹼能假說 (膽鹼假設)
  • 新藥需要2-3年
  • 老年癡呆症的重病度檢測
  • Amyloid假設
  • 抗乙型澱粉樣蛋白抗體的作用法
  • 維繫Amyloid假設的基礎科學
  • 如果Amyloid假設錯誤
  • 下一代治療方法βAmyloid受到注目
  • 正在開發的抗AB治療藥
  • 其他正在開發的老年癡呆症治療藥
  • 安全風險
  • 乙酰膽鹼酯酶抑制劑治療的標準
  • 新老年癡呆症治療藥的開發指南
  • 新的治療藥擴大市場
  • 現有的治療藥有相當的限制
  • 下一代治療藥仍遙遙無期、其他


  • 背景
  • 健康的腦部老化
  • 醫藥品療法並未得出良好結果
  • 植物化學物質方法
  • 植物抽取物·化合物已被寬泛重審
  • 認識功能
  • 歐洲的植物型天然產品
  • Galantamine
  • 鼠尾草
  • Lemon Balm
  • 長春蔓
  • 中藥型的天然產品
  • 銀杏
  • 人參
  • 石杉鹼甲
  • 其他中藥·日本的草藥
  • 行動性·心理性症狀
  • 癡呆症的行動性·心理性症狀
  • 整體的BPSD
  • 不安
  • 老年癡呆症的預防/穩定化
  • 結論


  • 老年癡呆症目前全球性流行病
  • 全球老年癡呆症盛行率
  • 美國的老年癡呆症患者·治療標準
  • 藥物是第一道防線
  • 全球老年癡呆症治療藥市場
  • 主要趨勢·課題
  • 製造商市場佔有率
  • Aricept的下降
  • Namenda是對症療法的主力
  • Aricept In Decline
  • Razadyne毀於學名藥
  • 臨床實驗中的BACE抑制劑
  • Gamma-Secretase Modulators、其他




The objective of this report is to provide a detailed analysis of Alzheimer's disease (AD) and the pharmaceutical drugs and medicinal plants used to treat and prevent it. It also provides an overview of the leading companies serving this market and their current and future product offerings.

This report will prove useful for people dealing with Alzheimr's disease, trying to prevent it, doing R&D on new drugs for it, or investing in this industry.

The conclusion of this report is that the future hope for treating and preventing Alzheimer's disease lies in medicinal plants.

Alzheimer's disease has become a major, public health problem. Globally, approximately 56 million people are estimated to be Alzheimer's sufferers in 2015. An estimated 5.6 million Americans now have Alzheimer's and, by mid-century, fueled in large part by the baby boom generation, the number of people living with AD in the United States is projected to reach 13.8 million.

At the moment, unfortunately, there is no cure available to impede the severe-type of AD, and only symptomatic treatment is applicable for the moderate and mild-types, which often lasts about 2-3 years.

Modern treatment strategies typically comprise of anticholinesterases, antioxidants, alpha and beta-secretase inhibitors, and N-methyl-D-aspartate (NMDA) receptor antagonists. But none of the current AD pharmaceutical drugs has demonstrated a disease modifying effect or is very efficacious at slowing progression. And next-generation treatments capable of slowing the disease progression will not reach the market for 3-5 years.

Further exacerbating the problem, the pharmaceutical industry is facing serious challenges as the drug discovery process for neurodegenerative diseases is becoming extremely expensive, riskier and critically inefficient. Also, a significant shift from a single-target to a multi-target drug approach, especially for chronic and complex disease syndromes, is taking place.

Because of the complexity of chemical content (in terms of both diverse classes and multiple analogues within any class) and variety of bioactivities, medicinal plants offer the prospect of the kind of built in poly-pharmacology that is increasingly apparent for orthodox drugs.

Also, medicinal plants can serve as chemopreventive agents, which induce therapeutic outcomes that modulate the aggregation process of beta-amyloid, and provide measureable cognitive benefits in the aging process. As a result, medicinal plants may be particularly relevant to long-term, potentially prophylactic use against AD by providing neuroprotection.

This report provides an estimate of global Alzheimer's disease pharmaceutical drug production, as well as estimates for several medical plants production that are useful in treating and preventing AD. A detailed analysis of current and future drug offerings is given, along with the companies producing and doing R&D on them. Additionally, a detailed analysis of medicinal plants that have been clinically evaluated for treating and preventing Alzheimer's disease is provided.

Table of Contents




  • Report Objectives
  • Methodology and Sources
  • Statistical Notes


  • Alzheimer's Disease Overview
  • Cholinergic Hypothesis
  • New Drugs 2-3 Years Away
  • Alzheimer's Severity Measures
  • Amyloid Hypothesis
  • How Anti-Amyloid Beta Antibodies Work
  • Basic Science Supports Amyloid Hypothesis
  • If The Amyloid Hypothesis Is Wrong
  • Next-Generation Treatments Focused On Beta-Amyloid
  • Anti-AΒ Therapies In Development
  • Bapineuzumab
  • Solanezumab
  • BIIB037
  • Crenezumab
  • Gantenerumab
  • BAN2401
  • Other Alzheimer's Therapies in Development
  • Tau And Neurofibrillary Tangles
  • Safety Risks
  • Acetylcholinesterase Inhibitors Are The Standard Of Care
  • New Alzheimer's Drug Development Guidelines
  • New Diagnostics Will Expand The Market
  • Existing Treatments Have Significant Limitations
  • Next-Generation Treatments Far Away


  • Background
  • Healthy Brain Aging
  • Pharmaceutical Approach Is Not Working
  • Phytochemical Approach
  • Plant Extracts and Compounds Have Been Extensively Reviewed
  • Cognitive Function
  • Natural Products Derived From European Plants
  • Galantamine
  • Sage
  • Lemon Balm
  • Periwinkle
  • Natural Products Derived from Traditional Chinese Medicines
  • Ginkgo
  • Ginseng
  • Huperzine
  • Other Traditional Chinese and Japanese Herbal Medicines
  • Behavioral and Psychological Symptoms
  • Behavioral and Psychological Symptoms of Dementia
  • BPSD as a Whole
  • Agitation
  • Alzheimer's Disease Prevention/Stabilization
  • Conclusions


  • Alzheimer's Disease Is Now A Pandemic
  • Worldwide Prevalence of Alzheimer's Disease
  • Global Market for Alzheimer's Disease Remedies
  • U.S. Alzheimer's Disease Sufferers And Treatment Metrics
  • Medications Are First Line of Defense
  • Global Market For Alzheimer's Drugs
  • Major Trends and Issues
  • Producer Market Shares
  • Aricept In Decline
  • Namenda Mainstay Symptomatic Therapy
  • Exelon Patch
  • Razadyne Destroyed By Generics
  • BACE Inhibitors In Clinical Trials
  • Gamma-Secretase Modulators
  • CAD106 Targets Mild AD Patients
  • Low Expectations For Rember
  • Davunetide Targets Tau/Microtubule Dynamics
  • Dietary Supplement Axona
  • PBT2 Fails To Meet Primary Endpoint
  • Nypta Offers A New Approach
  • New Therapeutic Approaches In The Next Decade
  • Bexarotene
  • Death Receptor 6
  • Gamma-Secretase Activating Protein
  • O-Linked N-Acetylglucosaminidase
  • Statins Not A Viable Therapy
  • NSAIDs Fall Short
  • Long-Term Outlook for Alzheimer's Disease Drugs


  • 1. Clinical Endpoints Used In Alzheimer's Disease Clinical Trials
  • 2. Comparison Of Alzheimer's Drugs In Development
  • 3. Alzheimer's Disease Diagnostics In Development
  • 4. Symptomatic Drugs For The Treatment Of Alzheimer's Disease
  • 5. European Plants And Their Constituents With Relevance For Dementia: Cognition
  • 6. Plants Used In Traditional Chinese Medicine And Their Constituents With Relevance For Dementia: Cognition
  • 7. Plants And Their Constituents With Relevance For Dementia: Behavioral And Psychological Symptoms
  • 8. Plants And Their Constituents With Relevance For Dementia: Disease Prevention
  • 9. Number of Alzheimer's Sufferers by Region (Million): 2015
  • 10. Alzheimer's Disease Drug Production Compared to Nutraceuticals, Marijuana, TCM, Green Tea and Turmeric Production ($ Million): 2015-2020
  • 11. U.S. Alzheimer's Disease Sufferers And Treatments Metrics (Million)
  • 12. Global Alzheimer's Disease Drug Sales ($ Billion): 2015-2020
  • 13. Alzheimer's Disease Drug Production By Type ($ Million): 2014-2020
  • 14. Alzheimer's Drugs Producers Sales and Market Shares ($ Million): 2013-2019
  • 15. Alzheimer's Disease Drugs R&D Pipeline by Product And Company
  • 16. Next Generation Alzheimer's Disease Drugs Market (Billion Yen): 2025-2035


  • 1. Targeting Of Beta-Amyloid In The Treatment Of Alzheimer's Disease
  • 2. Global Trajectory of Dementia Patients (Million): 2013-2050
Back to Top